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Abstract. In 2003, a stratified random sample survey was conducted in the Lao People’s Democratic Republic (Laos)
to study the availability and quality of antimalarials in the private sector. In 2012, this survey was repeated to allow a
statistically valid analysis of change through time. The counterfeit detection device 3 (CD-3) was used to assess packaging
quality in the field and HPLC and mass spectroscopy analysis chemical analysis performed. The availability of oral
artesunate monotherapies had significantly decreased from 22.9% (22) of 96 outlets in southern Laos in 2003 to 4.8% (7)
of 144 outlets in 2012 (P < 0.0001). All the samples collected in the 2012 survey contained the correct active pharmaceutical
ingredients (APIs) in contrast to the 21 (84%) falsified artesunate samples found in the 2003 survey. Although none of the
medicines found in 2012 survey had evidence for falsification, 25.4% (37) of the samples were outside the 90–110%
pharmacopeial limits of the label claim, suggesting that they were substandard or degraded. Results obtained from this
survey show that patients are still exposed to poorly manufactured drugs or to ineffective medicines such as chloroquine.
The quality of artemisinin-based combination therapies (ACTs) used in Laos needs to be monitored, since falsified ACTs
would have devastating consequences in public health.
BACKGROUND
There is increasing awareness that poor quality medicines,
both falsified (counterfeit) and substandard, are important
impediments to public health.1–5 The consequences of patients
taking poor quality medicines range from prolonged sickness
to death and societies may lose confidence in otherwise effec-
tive medicines and suffer major economic losses. Importantly
medicines with low amounts of active pharmaceutical ingredi-
ents (APIs) can engender drug resistance of pathogens.6,7
Artemisinin resistance threatens the efforts to control
and eliminate malaria. It has emerged on the Thai–Cambodia
border with recent evidence that it has spread to southern
Lao People’s Democratic Republic (Laos).7–9 To contain
artemisinin resistance and protect artemisinin-based combi-
nation therapies (ACTs), World Health Organization (WHO)
developed the Global Plan for Artemisinin Resistance Con-
tainment (GPARC) in 2011.10 Improved access to affordable,
quality-assured malaria diagnostics and treatment was one of
the main objectives, with special focus on the removal of oral
artemisinin-based monotherapies and substandard and coun-
terfeit medicines from the market.11
Artemisinin derivatives have been widely available in Laos
as oral monotherapies since the mid-1990s but the national
policy for treatment of confirmed uncomplicated Plasmodium
falciparum malaria has been co-formulated artemether–
lumefantrine (Coartem™) since 2005.12 Coartem (Novartis,
Suffern, NY) provided by the Global Fund to fight AIDS,
Tuberculosis and Malaria was introduced into Laos after
demonstration of in vivo malaria drug resistance to chloro-
quine and sulphadoxine–pyrimethamine (SP).13,14 ACTs have
been free in Laos for all ages in the public sector since 2005,
and artemisinin-based monotherapies have been withdrawn
since 2008, except artesunate injectables that are, as recom-
mended by WHO, the optimal treatment of severe malaria.
Althoughmalaria transmission has been decreasing in northern
and central Laos, it is still an important health problem in
remote and forested areas inhabited by ethnic minorities
and migrant workers in the south.15,16 Given that 6% patients
had prolonged P. falciparum clearance after oral artesunate
in southern Laos, along with the demonstration of the
P. falciparum Kelch13 mutations,9 artemether–lumefantrine
is at risk of losing its efficacy in the region.
Reports in the late 1990s in the Mekong region showed
high frequencies of poor quality antimalarials,17–20 with up
to 54% of the oral artesunate sample being falsified, usually
containing no antimalarial API.17,21–26 However, very few
data were acquired using random sampling that would allow
objective estimates, with confidence intervals (CIs), of the
proportion of a national medicine supply that is substandard
or falsified.5,27 In 2003, in a stratified random sample of the
quality of oral artesunate in Laos28, “mystery” shoppers were
requested to buy artesunate tablets from 180 private sector
outlets in 12 (of 18) randomly selected Lao provinces. Of the
25 outlets (13.9%) selling oral artesunate, 22 (88%; 95% CI:
68–97%) sold falsified artesunate, as defined by packaging
defects and confirmed by chemical analysis.
In 2012, this survey was repeated, using a similar sampling
design to allow, for the first time anywhere, an objective and
statistically valid analysis of change over time of the availability
and quality of antimalarials in the private sector. Furthermore,
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it was aimed at examining the change in frequency that outlets
sold oral artesunate monotherapy that is no longer recom-
mended, whether genuine, substandard, or falsified. The same
methodology that was used in 2003 was followed as much as
possible. The main difference was that the 2012 survey was
restricted to the five southern Lao provinces asmalaria incidence
had declined elsewhere in Laos in the intervening 9 years.16
METHODS
Setting. Laos has a population of ~6.6 million people with
the majority (63%) living in rural areas.12,14 Malaria transmis-
sion has declined over much of the country over the last
decade since the introduction of insecticide-treated nets
(ITNs)/long-lasting nets (LLNs), and the ACT/rapid diagnos-
tic tests (RDTs),14 but there remains a high incidence in the
south, especially Savannakhet, Salavan, Sekong, Champasak,
and Attapeu Provinces. Ethnic minority groups, forest fringe
inhabitants, seasonal migrants, and new forest settlers are
especially affected. All age groups are at risk but the majority
of patients are adult males and children < 15 years.12–14,29
P. falciparum accounts for the majority of Plasmodium spe-
cies (~87%) with P. vivax accounting for ~13% of infections.
Study design. A cross-sectional random sampling of pri-
vate medicine outlets was conducted in the five southern
Lao provinces starting in September 2012, for 4 weeks. One
urban and one rural district (i.e., stratified by urbanization)
were selected by random number tables from each of the
five southern provinces, and all outlets in these districts were
sampled. Districts were categorized by urbanization on the
basis of a consensus of the Lao Food and Drug Department
(FDD) and Food and Drug Quality Control Center (FDQCC)
staff, bearing in mind district population density, transport
conditions, and development.28 The districts selected were
Adsaphangthong and Sepon in Savannakhet, Salavan and
Toumlane in Salavan Province, Sekong (Lamarm) and Thateng
in Sekong Province, Samakkhixay and Sanamxay in Attapeu,
and Pakse and Sanasoumboun in Champasak Province (Figure 1
and Supplemental Table 1).
In the study of Sengaloundeth and others,28 only the private
sector was sampled. The public government sector is now
supplied with quality-assured ACTs.
Figure 1. Map of the districts selected and the outlets sampled during the 2012 survey in southern Laos. The (red) numbers refer to the
number of outlets sampled within each district.
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A 1 week pre-survey training was conducted in Vientiane,
Laos, including pretesting of the data collection tools and
debriefing process. The questionnaire was translated into
Lao and back-translated into English. Training for packag-
ing analysis with the U.S. Food and Drug Administration
(FDA) counterfeit detection device 3 (CD-3) was conducted
in July 2012.30
On arrival in the districts, the study team met with the
district and village authorities to update lists of existing
licensed pharmacies and unlicensed shops selling medicines
within the area. Acting as mystery shoppers, one male and
one female assistant procured antimalarial medicines inde-
pendently from all outlets identified in the selected districts.
Outlets were visited by a mystery shopper dressed as a
Lao manual worker stating: “I would like to buy some drugs
for my friend who is sick – we are traveling and work in
construction–may I see which ones you have so I can choose?”
Once some medicines have been dispensed, the mystery shop-
per enquired about the availability of other brands or products.
Twenty tablets of each preparation and five vials of paren-
teral antimalarial medicines were requested for each sample
and the number of units available was collected. Three
attempts were made to visit outlets closed at the time of the
survey. Each assistant was debriefed after each interaction
using a semi-structured questionnaire.
Comparative packaging analysis with genuine samples
(when available) was performed using the CD-3 later on the
same day of collection.
Inclusion criteria. All private pharmacy or drug sellers in
the study districts, whether registered or unregistered, were
eligible for inclusion in the survey. Itinerant drug sellers were
not included.
In Laos, private pharmacies are classified depending on
the qualifications of the licensee: class I pharmacies are run
by a qualified pharmacist with a university degree; class II are
run by an assistant pharmacist; class III are run by any medi-
cal professional, usually an auxiliary nurse or low-level phar-
macist (the licensee does not have to be a pharmacist or an
assistant pharmacist). Registered Private Clinics are run by
medical doctors after government working hours with at least
7 years of clinical experience in the public sector or by doc-
tors who have retired. Retired pharmacists, nurses, or health
workers who have worked for the government for at least 5
years can apply to run any of class I, II, or III pharmacies.17,31
Poor quality medicines were defined as falsified or substan-
dard based on WHO definitions. Falsified medical products
are products deliberately or fraudulently mislabeled with
respect to identity or source. In contrast, substandard medi-
cines are genuine medicines produced by manufacturers
authorized by the national medicine regulatory authority
(MRA), which do not meet quality specifications set for
them by national standards.32
A sample was defined as a group of apparently physi-
cally identical dosage units (e.g., tablets or vials) from one
brand and one batch obtained at the same time from the
same outlet. Samples were kept in a foam box and sent to
Vientiane as early as possible (within 3–4 days of collection)
for storage at +4°C (±2°C) in a refrigerator.
All data were double-entered in a pre-established EpiData
database. Samples were photographed and/or scanned. Data
were analyzed using STATA (v11.2, Stata Corp., College
Station, TX) and Microsoft Excel.
Laboratory analysis of the samples. Antimalarial samples
were sent for chemical analysis to the Centers for Disease
Control and Prevention (CDC) and the Georgia Institute of
Technology, both in Atlanta, GA.
Mass spectroscopy was used to determine as to whether
the sample contained the stated, or other API33,34 and the
content measurements of each API was determined using
high-performance liquid chromatography (HPLC).35 Between
three and five dosage units were tested for each sample (when
available) and the mean of the percentage API (%API) was
obtained. Twenty-two samples were sent to the London School
of Hygiene and Tropical Medicine (LSHTM) for HPLC con-
firmatory analysis as a quality control measure. Samples were
kept in foam boxes protected from light, excessive moisture, or
dryness. Temperature data loggers were included within ship-
ments to document appropriate temperature in transit.
Samples were classified as meeting the quality require-
ments if the amount of API in each of the units, as determined
from their content uniformity method,36–40 lay within the
range of 75.0–125.0% of the label claim. The number of units
within the 85.0–115.0% and the 90.0–110.0% ranges were
also specified (see Supplemental Table 2).
Since “yaa chud” are small plastic bags, commonly sold
individually in Laos, containing 4–5 tablets and capsules
without any labeling or written instructions,41 they were ana-
lyzed assuming that they were chloroquine and using the
standard dose of 250 mg chloroquine base per tablet. The
APIs in all the tablets were confirmed by ultraviolet (UV)
spectrum. Results were expressed as percentage of stated or
assumed API.
Packaging analysis was conducted, blinded to chemistry
and vice versa, by visual inspection and using the U.S. FDA
CD-3.30 The CD-3 is a nondestructive handheld battery-
powered tool that uses multiple light sources to screen for
differences in reflectance from the surfaces of dosage forms
and their packaging. Suspect medicines are screened in com-
parison to an authentic product and the differences in appear-
ance are observed. Before September 2012, attempts were
made to obtain genuine reference samples of all the different
brands and dosage forms of the medicines expected to be
sampled in the field. These samples were first screened with
the CD-3 to create a library of genuine characteristics and to
detect covert package markers for reference.
This report has been written following as far as possi-
ble the Medicine Quality Assessment Reporting Guidelines
(MEDQUARG)27,42,43 (see Supplemental Table 3). The results
have been reported to the Lao FDD and included in the
Worldwide Antimalarial Resistance Network (WWARN)
Antimalarial Quality (AQ) Surveyor.5,44 Ethical clearance
was granted by the Lao PDR National Ethics Committee
for Health Research (NECHR).
RESULTS
Survey description. A total of 147 outlets were sampled in
the 10 districts, 45 in the rural and 102 in the urban districts.
Of the outlets visited, three outlets were closed during all the
three visits and therefore only 144 were included in the study
(Supplemental Figure 1).
Registered outlets accounted for 97.2% (140) of those
eligible. Pharmacy classes I and II accounted for 30.9% (43)
and 30.9% (43) of outlets, respectively, and 33.8% (47) were
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pharmacy class III. Only 4.1% (6) of the registered outlets
were clinics, and one of the outlets sampled was a shop of a
registered pharmaceutical manufacturer, Pharmaceutical Fac-
tory No. 2. Only four unregistered outlets (2.7%) were found,
and they were general shops that were also selling medicines,
including antimalarial medication. Two of these shops were
in Sepon District, Savannakhet Province, and the other two
were in Sanasoumboun District, Champasak Province.
Mystery shoppers were asked by providers if they had a
blood test for malaria prior to buying antimalarial medicines
in 20.8% (30) of outlets. In 90% (27) of these outlets, the
providers suggested that the shopper should have a test for
malaria or offered the test himself/herself before buying the
medicines. Antimalarials were bought from 76.4% (110) of
the eligible outlets. Of the 23.6% (34) outlets where mystery
shoppers were unable to buy malaria medicines, in 14.7% (5)
of them, the provider refused to sell the drugs without a test
even if they had malaria medicines in stock, and 73.5% (25)
outlets did not stock antimalarial medicines at the time of
the survey. The provider was absent or offered a medicine
that was not an antimalarial in four outlets.
Medicines offered to mystery shoppers at registered and
unregistered outlets.Out of the 158 samples sold for the treat-
ment of malaria, 89.9% (142) were labeled as antimalarials
and 10.1% (16) samples were sold as loose tablets with no
label or packaging information; nine of these samples were
a combination of tablets or capsules with more than one type
of medicine (defined as yaa chud as given in reference41);
the other seven were loose tablets of only one type of medi-
cine sold in plastic bags.
Chloroquine was the medicine most frequently sold, account-
ing for 79.0% (128) of samples, including in four yaa chud.
The other antimalarials sampled were artesunate monotherapy
6.8% (11), quinine 3.7% (6), and artemether–lumefantrine
0.6% (1) (see Table 1).
Tablets accounted for 84.6% (137) of samples, with injections
and syrups accounting for 10.5% (17) and 2.5% (4), respec-
tively, including artesunate, quinine, and chloroquine vials.
Nine outlets (6.3%) sold artemisinin derivative monotherapy
and a total of eleven samples of artesunate were collected.
Seven 50-mg artesunate tablet blister packs were collected
(152 tablets) in one outlet in Sepon, one in Salavan, one in
Table 1
Description of the antimalarial medicines sampled in the 2012 survey
Labeled as API
No. of
samples % Dosage (mg) Form
No. of
samples
per brand Stated brand Stated manufacturer
Mean [price per
unit (tab, vial,
bottle, bag)
8,064 Lao
kips »USD 1]
Chloroquine
phosphate
85 52.5 250 Tablets 4 Malacin ANB Laboratories Co.,
Ltd., Bangkok, Thailand
662.5
250 Tablets 74 Maraquine CBF Pharmaceutical
Factory Pakse,
Champasak, Lao PDR
602.2
322.5 Injection 7 Malacin ANB Laboratories Co.,
Ltd., Bangkok, Thailand
3,428.6
Chloroquine 43 26.5 85 Syrup 4 Chloquine CBF Pharmaceutical
Factory Pakse,
Champasak, Lao PDR
12,000
100 Tablets 3 Nivaquine
(chloroquine
sulphate)
Sanofi-Aventis, France 750
Unknown Tablets 32 Unknown Unknown 361.2
Unknown Tablets 4 Included in
yaa chud
Included in yaa chud Included in
yaa chud
Artesunate 11 6.8 50 Tablets 6 Artesunat Pharbaco Central
Pharmaceuticals.
Central Pharmaceutical
Factory N ° 1, Hanoi,
Vietnam
2,291.7
50 Tablets 1 Artesunat Mekophar chemical
pharmaceutical
Joint-stock Company,
Ho Chi Minh City,
Vietnam
1,250
60 Injection 4 Artesunate Pharbaco Central
Pharmaceuticals.
Central Pharmaceutical
Factory N ° 1, Hanoi,
Vietnam
19,500
Quinine
dihydrochloride
6 3.7 600 Injection 6 Quinine
dihydrochloride
ANB Laboratories Co.,
Ltd., Bangkok, Thailand
3,291.7
Artemether–
lumefantrine
1 0.6 20/120 Tablets 1 Coartem Novartis Pharmaceuticals
Co., Suffern, NY
625
Yaa chud 9 5.5 Unknown Tablets/
capsules
9 Unknown Unknown 3,098
Loose
monotherapy
7 4.3 Unknown Tablets 7 Unknown Unknown 517.8
API = active pharmaceutical ingredient; USD = United States dollar.
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Samakkhixay and four outlets in Pakse districts. Six samples
were labeled as “Artesunat 50 mg tablets” with Pharbaco Cen-
tral Pharmaceuticals, Hanoi, Vietnam, as the stated manufac-
turer and 56% (72) of tablets were labeled as from the same
batch. The other brand collected (24 tablets) was “Artesunat
50 mg” with the stated manufacturer as Mekophar Chemical
Pharmaceutical Joint, Ho Chi Minh City, Vietnam. No oral
artesunate labeled as manufactured by Guilin Pharmaceutical
Co. Ltd. (Guilin, PR China) was found.†
Four artesunate injection samples were sold in two outlets
in Sepon and one in Salavan. All the samples were labeled as
manufactured by Pharbaco Central Pharmaceuticals.
Three of four bottles of chloroquine 85 mg/mL syrup sold
had expired at the time of the survey. One sample of artesunate
injection sold, expired a month after the survey ended.
The mean cost of oral chloroquine 250 mg treatment
(branded as Maraquine or Malacin) was 632.3 Lao Kips
(~USD 0.07) per tablet; chloroquine injection was 3,428 kip
(~USD 0.42) per vial and chloroquine loose treatment (with
no outer packaging) was 361.2 kip (~USD 0.04) per tablet.
The mean cost of artesunate tablet treatment (labeled as
Artesunat by Pharbaco Central Pharmaceuticals) was 2,291 kip
(~USD 0.28) per tablet and artesunate injection treatment was
19,500 kip (~USD 2.40) per vial.
Chemical quality of the antimalarial medicines. All of the
146 medicines labeled as antimalarials analyzed (142 samples
plus 4 chloroquine tablets found in the yaa chud samples)
contained the expected API. All except one sample had
all the units with a %API between 75–125% of the content
stated on the label. The failed sample was a chloroquine
injectable in which 3 of the 4 vials tested had a %API below
the 75% cutoff (API values: 64.5%, 70.3%, 62.8%, and 108%
per vial). Another nine samples had at least one of their
dosage units within a %API range of 75–85%. Seven of
these were chloroquine tablets labeled as Maraquine made
by CBF Pharmaceuticals, Champasak, Lao PDR; the other
two were chloroquine tablets included in the yaa chud
(see Figure 2).
The majority of the samples (93.1% [136]) had their unit’s
%API between 85% and 115%; and 74.6% (109) had their
units between 90% and 110%. Twenty-seven (18.5%) samples
contained units outside the 90–110% API range but within
the 85–115% cutoff; 16.4% (24) samples had units with
85–90% API of the label claim and only 2.0% (3) samples
had units > 110% API (see Supplemental Tables 4 and 5).
Inter-tablet variability was also measured for 3–5 tablets
per dosage units from the same sample. Artesunate and qui-
nine had high variability between their units with mean
(RSD) of 29.9% (95% CI: −1.2; 61.1) and 35.5% (95% CI:
−18.5; 89.6), respectively (see Figure 3, Supplemental Fig-
ures 2–4 and Supplemental Table 6).
Results obtained from the confirmatory analysis of 15 sam-
ples at the LSHTM were consistent with the analysis in
Atlanta with a variation of ±5% between analyses. Higher dis-
crepancies were observed in 6 (4.1% of all) samples with a unit
variation ranging from 12.1% to 42.1%. The discordant sam-
ples were three 250 mg chloroquine phosphate tablet samples
labeled as Maraquine manufactured by CBF Pharmaceuticals,
one sample of chloroquine injection 322.5 mg labeled as
manufactured by ANB Laboratories (Bangkok, Thailand),
one sample of chloroquine tablets 250 mg found in the yaa
chud, and one sample of artesunate 60 mg injection stated as
manufactured by Pharbaco Pharmaceuticals.
Packaging analysis with CD-3. CD-3 analysis was con-
ducted on only 23 samples as genuine comparators were not
available for 64.8% (105) of the medicines sampled. An addi-
tional 34 samples of loose chloroquine tablets had no outer
packaging. All those chloroquine tablets collected had the
same tablet design and were consistent with each other under
the CD-3 light but were not consistent when analyzed against
the only genuine comparator available. No conclusions could
be made without the packaging but it suggests that they were
from a different manufacturer, brand, or batch when com-
pared with the genuine product. The difference could be due
to the excipient variation between different manufacturers
or the coating of the chloroquine samples, or medicines may
have been degraded due to poor storage conditions.
†Guilin Pharmaceutical Co. Ltd. stopped manufacturing monotherapy
artesunate in 2008.
Figure 2. Frequency of antimalarial mean active pharmaceutical
ingredient (%API) found in the samples (N = 146). Dashed line
represents 75–125% cut off and solid line 90–110%.
Figure 3. Inter-unit variability measured as the relative standard
deviation (RSD) and mean active pharmaceutical ingredient (%API)
by medicine. It includes both intravenous and oral forms. Numbers
above bars represent sample size.
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Another 10 samples were consistent with their genuine
comparators, includingoneartemether–lumefantrine (Coartem),
two oral artesunate samples, four oral chloroquine, and three
quinine injection vials.
Thirteen samples were not consistent with the genuine
comparator when analyzed with the CD-3, including five
oral artesunate blisters, five chloroquine injection vials, and
three quinine injection vials. These medicines are under inves-
tigation with the stated manufacturer to try to understand the
significance of the differences observed (Table 2). Discrepan-
cies may be a result of degraded products; artesunate tablets
stored at higher temperatures fluoresce more strongly using
the CD-3. All except one of the samples that failed pack-
aging analysis had a %API between 90% and 110%, with
one chloroquine sample failing both chemistry (mean %API
65.9%) and packaging analysis. This sample (code 4-1601-02-2)
may be falsified or possibly substandard.
Content of yaa chud and loose tablets. Nine unlabeled
plastic bags of diverse medicines were sold to the mystery
shoppers when they asked for malaria treatment. Each
yaa chud treatment included a median (range) of 5 (3–10)
individual plastic bags with 5–7 tablets per capsules per
bag. Mass spectrometric tablet analyses demonstrated that
each bag contained vitamin B and vitamin C and analgesics,
acetaminophen, or ibuprofen. Chloroquine and the antibiotic/
antimalarial tetracycline were included in 4 of the 9 yaa
chud, but other antibiotics, such as erythromycin, ampi-
cillin, and chloramphenicol, were also found (Supplemental
Table 7). Tablets of the sulfonylurea chlorpropamide and
the steroid betamethasone were found once in the plastic
bags. No artemisinin derivatives were found in the yaa chud
unlabeled samples.
Seven samples were dispensed to mystery shoppers as loose
monotherapy tablets in plastic bags; six of these bags were
dispensed to be taken together with an antimalarial medicine.
Six out of seven of these plastic bags contained vitamins:
three samples were B group (B1 or B6), two samples con-
tained vitamin C, and one contained multivitamins. One
sample contained diclofenac, a nonsteroidal anti-inflammatory
drug. The antimalarial Coartem was given with a bag of vita-
min B1 and a bag of multivitamins, two samples of chloro-
quine were dispensed together with two bags of the vitamin B
group, and one additional chloroquine sample with loose vita-
min C tablets. One oral artesunate was dispensed with a bag
of vitamin C tablets and the one bag dispensed without anti-
malarials contained diclofenac tablets.
The mean cost of yaa chud treatments was 16,333 Lao
kips (»USD 2.03) or 3,098 Lao kips (»USD 0.38) per bag.
Except at two outlets, advice about how to take the yaa
chud was given with specification to be taken twice a day
(Supplemental Table 7).
DISCUSSION
Falsified (counterfeit) artesunate was discovered in the
late 1990s in mainland southeast (SE) Asia, and contained no
or inadequate amounts of artesunate. Concurrent surveys
investigating the quality of medicines in Laos demonstrated
the availability of poor quality ampicillin, tetracycline, chlo-
roquine, and aspirin ranging from 22% to 46% of 300 and
366 samples, respectively.17,19,20,45 The frequency of falsified
oral artesunate in the private sector as determined by con-
venience sampling was as high as 38%.5,21–23,28 A random sur-
vey in 2003 in Laos estimated that 88% (95% CI: 68–97%) of
outlets that sold artesunate, sold falsified artesunate. Results
obtained from this 2012 survey in Laos indicate that there has
been a significant improvement since 2003, with no falsified
artesunate detected (P < 0.0001). Importantly, the availability
of oral artesunate monotherapies has significantly decreased
from 22.9% (22 out of 96 outlets) in southern Laos in 2003 to
4.8% (7 out of 144 outlets) in 2012 (see Figure 4), (non-paired
cross-sectional with Fisher’s exact test P < 0.0001).
Even though the majority of the samples contained the
correct mean amount of API, there was a great variation of
the quantity of API within the samples and between their
units. Although 93.1% samples had all dosage units between
Table 2
Packaging analysis of the samples with the FDA CD-3
API
No of samples
collected
(N) %
No. of samples
with no
comparator
No. of samples
with no
full packaging
CD-3 analysis consistent
Yes No
Artemether–lumefantrine 1 0.6 0 0 1 0
Artesunate 11 6.8 4 0 2 5
Chloroquine 128 79 85 34 4 5
Quinine dihydrochloride 6 3.7 0 0 3 3
Yaa chud/loose tablets 16 9.9 16 0 0 0
Total 162 100 105 34 10 13
API = active pharmaceutical ingredient; CD-3 = counterfeit detection device 3; FDA = Food and Drug Administration;.
Figure 4. Comparison of availability and quality of artesunate
monotherapy tablets samples between the 2003 and 2012 surveys.
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85% and 115% API% of the label claim, nine poor quality
samples had dosage units containing between 75% and 85%
API. No genuine comparator was available to ascertain
whether the samples were falsified.
Of outlet sellers, 14.7% (5) were reluctant to sell malaria
medicines without a RDT, and only chloroquine was avail-
able in the majority of the outlets. Artemether–lumefantrine
Coartem from the public sector was available at only one
outlet, in Sepon district, that was part of the Public Private
Mix (PPM) program and was therefore not diverted.
Major changes have occurred in the intervening 9 years
that may have had a decisive role in the improvement of
antimalarial quality in Laos. Control strategies such as
ITNs/LLNs, malaria early diagnosis and adequate treatment
(EDAT) policy and an increased level of surveillance and
reporting through village health volunteers have probably had
a positive impact on malaria incidence. Malaria diagnosis and
treatment have been decentralized down to the village level
with a focus on ethnic minorities in remote areas.46 It is likely
that patients have better access to antimalarials and health
services than they did in 2003.14
The dramatic reduction in trade and use of artesunate
monotherapy that was available and falsified on an enormous
scale 10 years ago is the major driver for the positive change.
Guilin Pharmaceuticals Co. Ltd. stopped trading artesunate
monotherapy tablets in 2008. In addition, in 2005 Lao started
using Global Fund ACTs in the public sector, and in 2008
the PPM program for malaria started,14,46 presumably reduc-
ing the need for patients to seek monotherapy. Six, out of the
ten districts sampled, were part of the PPM program.
Pharmaceutical legislation has also been updated and a
new quality assurance system has been implemented with
technical and financial support from international organiza-
tions. The Law on Drugs and Medical Products was amended
to ensure adequate registration, distribution, and supply of
all medical products. Furthermore, four regional warehouses
and one central warehouse in Vientiane were constructed
with support from Japan International Cooperation Agency
(JICA).20,31,46–48 Institutional capacity of the FDQCC in drug
analysis has also been improved and pharmacy inspectors
trained by the Drug Quality and Information (USP DQI)
project from the United States Pharmacopeia (USP) and
the WHO.47 Since 2003, 12 sentinel sites have been recruited
using the Global Pharma-Health Fund (GPHF) MinilabÒ.45
Training on good laboratory practice (GLP), good distribution
practice (GDP), good procurement practice (GPP), and good
manufacturing practice (GMP) has been conducted.
Programs aimed at increasing awareness and communi-
cation campaigns against falsified medicines have been con-
ducted, but their efficacy has not been measured.22,49–51 In
this survey, out of 144 outlets, 11.8% (17) had some form
of information posted on falsified medicines and 4.8% (7)
had the WHO “cobra” poster.52 One-third (31.6%) of the sam-
ples collected had no labeling or no outer packaging. Half of
the medicines collected (50%) were labeled in Lao language,
9.5% samples were labeled in Thai, and 6.9% samples were
labeled in Vietnamese (all the artesunate samples) with 1.9%
in French. It is highly recommended that medicines should
be sold in their original packaging and the dose regimes
specified in the local Lao language should be included. It is
important to note that some artesunate monotherapy was still
available, which is not recommended and that some samples
collected in the 2012 survey were not registered (the oral
artesunate, chloroquine 250 mg tablets labeled as from ANB
Laboratories, Cloquine and Nivaquine). All these suggest that
further interventions are required.
The significance of content variability38 is unclear as there
is little objective evidence, informed by pharmacokinetic–
pharmacodynamic analysis, as to how many failed dosage
units in a sample should be regarded as minimally acceptable;
ideally it should clearly be none. There have been reports
describing dose-to-dose variations in suspected falsified medi-
cines, and this needs further study.53
There is a great difficulty in differentiating substandard and
degraded medicines as there is usually insufficient chemical
information available to distinguish them. The importance of
degradation for the samples collected in this survey is unclear.
No outlet stored their medicines in an air conditioned room,
95.8% (138) of 144 were stored in cabinets or drawers inside
the shop, and only 4.1% (6) dispensed their medicines from
an open shelf or a container.
Despite the apparent improvement in reduction of the
availability of oral artesunate monotherapy, the presence and
permitted sale of yaa chud was identified as a key issue.
Some yaa chud sold to mystery shoppers were found to
contain only analgesics that would not have had any antima-
larial effect and would have been a waste of patient’s money.
The finding of steroids and sulfonylureas within yaa chud is
also of great concern as they can cause serious side effects.
Betamethasone is a glucocorticoid with anti-inflammatory
and immunosuppressant effects and has been associated with
hypoglycemia and leukocytosis in newborns exposed in utero.
Systemic steroids are risk factors for diabetes and hence for
melioidosis (Burkholderia pseudomallei).54 Chlorpropamide, a
sulfonylurea for treatment of type 2 diabetes, risks hypoglyce-
mia and is potentially teratogenic.55 In addition, 7 (77%) of
the yaa chud contained antibiotics as a single dosage unit
that lack therapeutic effect and may promote antibiotic resis-
tance. Antibiotics such as chloramphenicol can cause bone
marrow toxicity, albeit a rare adverse effect but that would
be expected to be fatal in rural Laos. Medical prescription
and supervision should be a requisite for dispensing such
medicines. Furthermore the high frequency of chloroquine
dispensing is alarming as this will not be efficacious against
falciparum malaria11; vivax malaria accounts for only 5–10%
of malaria episodes in Laos. Thus, widespread chloroquine use
would inhibit any possible return of falciparum malaria chlo-
roquine susceptibility.56 Parenteral chloroquine is no longer
recommended for use by WHO57 and it should not be available.
The handheld portable CD-3 device was a practical and
useful tool with the ability to screen suspicious medicines
quickly in the field. However the lack of genuine comparators
hampered the number of samples that could be tested, only
35.2%. This emphasizes the need for greater cooperation in
obtaining authentic medicines from manufacturers.
The CD-3 analysis picked up some inconsistent samples
and variation between batches that are being investigated
further. These could have arisen by falsification or by changes
of ink, graphics, or pigments during manufacture that we were
unaware of. Close collaboration with the pharmaceutical
industry will help to clarify such discrepancies (see Supple-
mental Figure 5).
Although the CD-3 device is portable and very user
friendly, sample analysis may be influenced by the subjectivity
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of the operator. The device will need to be made more robust
to be able to empower pharmacy inspectors and customs
agents in remote hot and cold monitoring sites or checkpoints
in the field.
The study has several important limitations. Given that
unlicensed outlets are illegal, it is very difficult to be certain
that all such outlets were found and that those found sold
the mystery shoppers the medicines that they had in stock.
Dissolution and disintegration tests were not performed and
the number of dosage units per sample was low. Indeed, a
problematic and unresolved issue remains of uncertainty to
the number of dosage units that should be collected in the
field. Lacking confirmed genuine comparator packets for
105 samples and uncertainty of the diversity of genuine pack-
aging make it difficult to interpret some differences using
the CD-3. Furthermore, sample analysis with the CD-3 device
may have been influenced by the subjectivity of the operator
although, for oral artesunate, diagnostic accuracy was very
high.30 In both 2012 and 2003 surveys, itinerant sellers were
not sampled but they may stock poor quality antimalarials
and may reach remote communities.
In SE Asia the private sector is a major source of antima-
larial drugs and many patients have relied on artesunate
monotherapy in the recent past. As artesunate tablet therapy
has not been approved in Laos since 2008, the oral artesunate
sold in both surveys was therefore illegal.
Although there are burgeoning reports of an epidemic
of falsified ACTs in malarious Africa,4 there have been no
reports of these in SE Asia. This is encouraging but is incon-
sistent with recent history and more monitoring of the ACT
supply is needed.
CONCLUSIONS
Even though the evidence from these two sequential
surveys suggests that the quality of antimalarial medicines
has improved over the last decade, the inter-tablet variability
found in the samples and the low amounts of API found in
some chloroquine vials suggest that substandard medicines
may continue to be available in southern Laos. Substandard
medicines are important and poorly recognized causes of
resistance and poor outcome to individual patients.6,7 Chloro-
quine was commonly available raising concern that this anti-
malarial may be used by private outlets to treat falciparum
malaria when it is known to be efficacious only against for
P. vivax, P. ovale, and P. malariae. Parenteral chloroquine
has no role in antimalarial treatment in Laos and should
be removed from circulation. Artesunate oral monother-
apy was still available in southern Laos, albeit on a much
reduced scale, despite the subsidy on ACTs. Therefore, the
strengthening of national and international regulatory over-
sight is needed.58
Despite the apparent improvement in the overall antima-
larial quality, the yaa chud pose a serious risk to public health.
Patients may be exposed to dangerous drug interactions and
adverse effects and to medicines lacking therapeutic efficacy.
The low doses of antibiotic found in the yaa chud may also
engender drug resistance. Public engagement campaigns, similar
to those that have been conducted in Thailand, against yaa chud
may help in reducing their use and risks to the population.41
Closer collaboration with the pharmaceutical industry will
facilitate obtaining authentic medicines necessary to conduct
packaging analysis and will help to clarify the observed dis-
crepancies between genuine and suspect samples. Medicines
are fundamental to strategies for effective reduction of mor-
tality and morbidity and their good quality is essential for
ensuring their efficacy and safety.
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